^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Cholangiocarcinoma
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Hormone Receptor Positive Breast Cancer)
    New
    Excerpt:
    Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):...in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Oncol
    Title:

    Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance

    Published date:
    04/08/2022
    Excerpt:
    We obtained CCA tissue from patients who underwent radical resection of cholangiocarcinoma...Tissue of CC6062 was proved to be HER2-overexpressed…both numbers and sizes of CC6062 organoids were drastically reduced after being treated by lapatinib.
    DOI:
    https://doi.org/10.3389/fonc.2022.860339